SB17170 Phase 2 Trial in IPF Patients

Inclusion Criteria:

1. Adult male/female 40 years or older at the time of obtaining informed consent

2. Patients diagnosed with idiopathic pulmonary fibrosis who meet the followingcriteria:

• Patients with idiopathic pulmonary fibrosis who are confirmed by chestHigh-Resolution Computed Tomography (HRCT) scan

• Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT patternconsistent with a diagnosis of idiopathic pulmonary fibrosis confirmed throughcentral reading of chest HRCT before the baseline visit

3. Patients with a history of idiopathic pulmonary fibrosis treatment who meet thedefined criteria

4. Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at thescreening visit

5. Patients meeting pulmonary function test criteria at the screening visit

6. Patients who have received the explanation of this clinical trial and voluntarilyagreed and signed the informed consent form

Exclusion Criteria:

1. When there is a primary disease showing UIP patterns (rheumatoid arthritis-relatedinterstitial lung disease, connective tissue disease-related interstitial lungdisease, etc.) and/or other clinically significant lung abnormalities

2. Patients with confirmed acute exacerbation of IPF within 6 months prior to screeningand/or during the screening period

3. Patients with lower respiratory tract infections requiring antibiotic treatment

4. Patients who underwent major surgery within 3 months before screening or have majorsurgery planned during the clinical trial

5. Patients with a history of malignancy or documented evidence of active or suspectedmalignancy within 5 years prior to screening

6. Patients with evidence of active infection

7. Patients with the following cardiovascular and cerebrovascular diseases at the timeof screening:

• Severe hypertension within 3 months

• Myocardial infarction or unstable angina within 6 months

• History of thrombotic events within 6 months

• Diagnosis of heart failure within 6 months

8. Patients with pulmonary hypertension

9. Patients who are unable to take drugs orally or have a history of majorgastrointestinal surgery or pathological findings that may affect the absorption ofthe investigational product

10. Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B orC